177Lu-DTPA-SC16.56

N/A

Report date: 2026/04/15 20:02:38
NME

Base Information

Drug Name177Lu-DTPA-SC16.56
Drug Alias Name177Lu-DTPA-SC16.56
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionDelta-like protein 3 modulatorsPositron-emission tomography enhancers
TargetsDelta-like protein 3
Therapy Area/IndicationsNeuroendocrine Carcinoma of LungProstatic NeoplasmsLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsNeuroendocrine Carcinoma of LungProstatic NeoplasmsLung Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A